Roivant Sciences stock

ROIV · NASDAQ · USD

$39.53Change from previous close: −1.15%Absolute change: −$0.46

Close · November 13, 2026

Price history

+92.27% over the period

1 year: from $20.56 (November 13, 2025) to $39.53 (November 13, 2026), +92.27%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 13, 2026$39.53
October 30, 2026$36.91
September 30, 2026$36.57
August 31, 2026$34.64
July 31, 2026$33.91
June 30, 2026$35.39
May 29, 2026$29.99
April 30, 2026$28.53
March 31, 2026$27.70
February 27, 2026$28.94
January 30, 2026$21.62
December 31, 2025$21.70
November 28, 2025$20.81
November 13, 2025$20.56

At a glance

  • The company

    Clinical-stage biopharmaceutical company developing medicines for autoimmune, inflammatory, and rare diseases

  • Latest results

    Quarter to September 30, 2026 · EPS -$0.18 (estimate -$0.37)

TickerLandia's take on Roivant Sciences

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$18.32
52-wk high$42.50

−6.99% from the 52-week high

Analysts · 13 analysts

Average target$48.91+23.73% vs. price

Buy 11 · Hold 2 · Sell 0 · Strong buy

TickerLandia Fingerprint: Roivant Sciences

Compared with similar companies: very strong momentum, very high financial strength, and very low profitability.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.

1 dimension without enough data. Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Roivant Sciences is cheaper than similar companies

Roivant Sciences's Price/book: 6.29, −13% against the median of a group of 11 similar companies (7.20).

Compared with 11 similar companies

Roivant Sciences's metrics compared with similar companies
MetricRoivant SciencesPosition in the groupBand
Operating margin-17,875.4%Low
ROE-8.5%Low
Debt/equity0.02Low
Price/book6.29Middle
Net margin-3,535.0%Low

Grey band: the middle half of the group; tick: the median; dot: Roivant Sciences. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$1.44M

Latest quarter · Q2 2026

Net income

-$189.84M

Latest quarter · Q2 2026

Quarterly net margin

-13,164.8%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$26.39B
EPS
-$0.59
Volume
6.57M
Daily trading
€295.58M

How Roivant Sciences is changing

All results
  • Revenue fell 19.1% a year on average over the last 5 years

  • Operating margin fell from −2,565.9% to −15,495.2%

  • Less cash than profit: free cash flow equal to -61% of net income

Returns

Roivant Sciences returns

$1,000 invested in Roivant Sciences 5 years ago, on November 15, 2021, would be worth $4,892 today: +389.23% in total, +37.43% per year. This is the price return only: dividends are excluded.

PeriodRoivant SciencesS&P 500$1,000 becomes
1 month+18.53%−3.12%$1,185
6 months+35.28%+1.58%$1,353
Year to date+82.17%+10.46%$1,822
1 year+92.27%+12.23%$1,923
3 years+336.80%+71.41%$4,368
5 years+389.23%+61.48%$4,892

Over the last 6 months it has done better than 73% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

Roivant Sciences: technical analysis

Roivant Sciences is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 5.5% below its all-time closing high ($41.85, November 11, 2026).

Trend
Upward
RSI (14 sessions)
57
Between 30 and 70
vs 200-session average
+22.34%

Support and resistance

Price areas where Roivant Sciences has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last price$39.53
  3. Support$38.19−3.39%4 touches, last on October 22, 2026
  4. Support$35.63−9.87%2 touches, last on November 3, 2026
  5. Support$33.05−16.39%5 touches, last on October 14, 2026

Volatility and risk

Over the last year it has moved roughly in line with the S&P 500.

Beta (1 year) vs S&P 500
1.13
Volatility (60 sessions, annualised)
54.1%
Largest fall in the last year
−20.23%

Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Roivant Sciences: seasonality

Average monthly price change over 6 years

−7.2%Jan+5.3%Feb−8.8%Mar+2.2%Apr+3.5%May+4.3%Jun+2.7%Jul+1.1%Aug+2.0%Sep+8.6%Oct+2.5%Nov+23.2%Dec

Over the last 6 years, the strongest month for Roivant Sciences has been December: +23.19% on average, positive in 4 years out of 5. The weakest has been March: −8.76% on average, positive in 0 years out of 6. November, the current month, has been positive in 4 years out of 5 (+2.51% on average).

Show chart data
MonthAverageMedianPositive years
January−7.16%−3.14%2 of 6
February+5.26%−1.85%2 of 6
March−8.76%−6.96%0 of 6
April+2.16%+3.21%5 of 6
May+3.55%+2.51%3 of 6
June+4.26%+2.29%5 of 6
July+2.68%+0.50%4 of 6
August+1.05%+1.28%4 of 6
September+2.02%−2.35%3 of 6
October+8.61%+0.51%4 of 6
November+2.51%+4.28%4 of 5
December+23.19%+17.47%4 of 5

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Roivant Sciences and its competitors

Headquartered in London and founded in 2014, Roivant Sciences Ltd. develops medicines and related technologies aimed at immune-mediated and cardiopulmonary conditions. Its clinical pipeline is built around antibodies such as IMVT-1402 and batoclimab, the small molecule brepocitinib, and mosliciguat, an inhaled sGC activator that is the lead program and targets pulmonary hypertension linked to interstitial lung disease. These candidates are still in development, with target indications that include Graves' disease, rheumatoid arthritis, myasthenia gravis, thyroid eye disease and dermatomyositis.

Headquarters
London, United Kingdom
Employees
721
Founded
2014
Chief executive
Matthew Gline
Roivant Sciences and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Roivant SciencesROIV$26.39B-17,875.4%—+35.28%
InsmedINSM$26.58B-41.7%—+2.69%
IncyteINCY$24.66B32.2%61.7+22.41%
Revolution MedicinesRVMD$37.27B-853.0%—+14.91%
Alnylam PharmaceuticalsALNY$22.11B19.5%8.34−43.38%
BioNTechBNTX$21.22B-55.4%—−7.19%

Same industry or related industries, similar size. Compare Roivant Sciences with its competitors · Full profile